These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 533260)

  • 1. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.
    Francke EL; Appel GB; Neu HC
    Antimicrob Agents Chemother; 1979 Dec; 16(6):788-91. PubMed ID: 533260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.
    Giron JA; Meyers BR; Hirschman SZ; Srulevitch E
    Antimicrob Agents Chemother; 1981 Feb; 19(2):279-83. PubMed ID: 6214987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Godin M; Fillastre JP
    Antimicrob Agents Chemother; 1980 Mar; 17(3):344-9. PubMed ID: 7425600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin pharmacokinetics in subjects with chronic renal failure.
    Thompson MI; Russo ME; Matsen JM; Atkin-Thor E
    Antimicrob Agents Chemother; 1981 Mar; 19(3):450-3. PubMed ID: 6454382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous azlocillin kinetics in patients on long-term hemodialysis.
    Aletta JM; Francke EF; Neu HC
    Clin Pharmacol Ther; 1980 Apr; 27(4):563-6. PubMed ID: 7357815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of intravenous mezlocillin in chronic hemodialysis patients.
    Francke E; Mehta S; Neu HC; Appel GB
    Clin Pharmacol Ther; 1979 Aug; 26(2):228-31. PubMed ID: 455891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
    Garg DC; Baltodano N; Perez GO; Oster JR; Jallad NS; Weidler DJ
    Pharmacology; 1985; 31(4):189-93. PubMed ID: 4059323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hemodialysis on piperacillin pharmacokinetics.
    Heim-Duthoy KL; Halstenson CE; Abraham PA; Matzke GR
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):680-4. PubMed ID: 3818147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.
    De Schepper PJ; Tjandramaga TB; Mullie A; Verbesselt R; van Hecken A; Verberckmoes R; Verbist L
    J Antimicrob Chemother; 1982 Feb; 9 Suppl B():49-57. PubMed ID: 6460734
    [No Abstract]   [Full Text] [Related]  

  • 12. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP
    Antimicrob Agents Chemother; 1981 Jun; 19(6):965-71. PubMed ID: 6455967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Ozawa Y
    Antimicrob Agents Chemother; 1984 Nov; 26(5):647-51. PubMed ID: 6097172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxalactam pharmacokinetics during hemodialysis.
    Aronoff GR; Sloan RS; Mong SA; Luft FC; Kleit SA
    Antimicrob Agents Chemother; 1981 Apr; 19(4):575-7. PubMed ID: 6454386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.
    Patel IH; Bornemann LD; Brocks VM; Fang LS; Tolkoff-Rubin NE; Rubin RH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):46-50. PubMed ID: 4037777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.
    Appel GB; Neu HC; Parry MF; Goldberger MJ; Jacob GB
    Antimicrob Agents Chemother; 1976 Oct; 10(4):623-5. PubMed ID: 984799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.